Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
3(100.0%)
3Total
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05429073Phase 1Completed

A Study of RGLS8429 in Healthy Volunteers

Role: lead

NCT05521191Phase 1Completed

A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease

Role: lead

NCT04536688Phase 1Completed

A Study of RGLS4326 in Patients With Autosomal Dominant Polycystic Kidney Disease

Role: lead

All 3 trials loaded